Inhibition of eukaryotic initiation factor 4E by tomivosertib suppresses angiogenesis, growth, and survival of glioblastoma and enhances chemotherapy's efficacy
Fundamental & Clinical Pharmacology · 2023
DOI: 10.1111/fcp.12877 ↗Kurz gefasst
Fachartikel in der Zeitschrift Fundamental & Clinical Pharmacology, 2023. Verfasst von Qi Zhang und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science, Xiangyang, Hubei Province, China. Hauptthemen laut MEDLINE: Protein Serine-Threonine Kinases, Glioblastoma. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: Xiangyang Central Hospital.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Glioblastoma is characterized by extensive vascularization and is highly resistant to current therapy. Identification of drugs that target tumor directly and angiogenesis processes present an effective therapeutic strategy for glioblastoma. Mnk kinase is required for the activation of eukaryotic initiation factor 4E (eIF4E), which mediates translation of oncogenic proteins. We investigated the effects of tomivosertib, a novel MAPK‐interacting kinase (MNK) inhibitor, on glioblastoma angiogenesis, growth, and survival. We found that tomivosertib inhibited growth and induced caspase‐dependent apoptosis in various glioblastoma cell lines. Tomivosertib disrupted glioblastoma endothelial cell capillary network formation, growth, and survival. Mechanistically, tomivosertib acted on glioblastoma via suppressing MNK‐dependent eIF4E phosphorylation and activation in tumor and endothelial cells. We further found that temozolomide activated eIF4E and this was reversed by tomivosertib. Using glioblastoma xenograft mouse model, we demonstrated that temozolomide and tomivosertib combination had higher efficacy than tomivosertib alone. Of note, tomivosertib inhibited glioblastoma angiogenesis and decreased p‐eIF4E level in mice. We finally showed that p‐eIF4E activation was a common molecular feature in glioblastoma patients. Our pre‐clinical findings suggest that tomivosertib is a useful addition to the treatment armamentarium for glioblastoma and that targeting MNK‐eIF4E pathway represents a therapeutic strategy to overcome glioblastoma chemoresistance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science, Xiangyang, Hubei Province, China.
- Department of Neurosurgery, Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science, 14 Dong Street, Xiangcheng District, Xiangyang, 441021, Hubei Province, China.
ORCID-Profile: Tingwei Xu
Förderung
- Xiangyang Central Hospital
Zitieren
APA
Zhang, Q., Zhao, J., & Xu, T. (2023). Inhibition of eukaryotic initiation factor 4E by tomivosertib suppresses angiogenesis, growth, and survival of glioblastoma and enhances chemotherapy's efficacy. Fundamental & Clinical Pharmacology. https://doi.org/10.1111/fcp.12877
Vancouver
Zhang Q, Zhao J, Xu T. Inhibition of eukaryotic initiation factor 4E by tomivosertib suppresses angiogenesis, growth, and survival of glioblastoma and enhances chemotherapy's efficacy. Fundamental & Clinical Pharmacology. 2023. doi:10.1111/fcp.12877
BibTeX
@article{Zhang2023,
author = {Zhang, Qi and Zhao, Juan and Xu, Tingwei},
title = {Inhibition of eukaryotic initiation factor 4E by tomivosertib suppresses angiogenesis, growth, and survival of glioblastoma and enhances chemotherapy's efficacy},
journal = {Fundamental & Clinical Pharmacology},
year = {2023},
doi = {10.1111/fcp.12877}
}
EUVIMED